Product Reports Resources Pricing Login Book a demo

EGenesis

Biotech & Life Sciences · Cambridge, United States · Founded 2015

A gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues, and cells to address the global organ crisis MoreLess

eGenesis is a biotechnology startup that operates in the healthcare sector, specifically in the field of organ transplantation. The company's mission is to address the critical shortage of transplantable organs and cells, a problem that affects over 100,000 people in the U.S. alone. To do this, eGenesis is developing genetically engineered porcine kidneys that are compatible with human bodies, a concept they refer to as Human Compatible (HuCo™) organs and cells.

The company's business model revolves around leveraging advanced genetic engineering techniques to create these HuCo™ organs and cells. Once developed, these organs can be transplanted into patients with failing organs, potentially saving their lives and improving their quality of life. The company's primary clients are individuals in need of organ transplants, a demographic that is constantly growing due to the increasing gap between organ demand and supply.

eGenesis generates revenue by selling these genetically engineered organs to healthcare providers who perform the transplants. The company's work is not only potentially life-saving but also financially promising given the high demand for transplantable organs and the limited supply.

In summary, eGenesis is a pioneering biotech startup that is pushing the boundaries of organ transplantation by developing genetically engineered porcine organs that can be transplanted into humans. The company's innovative approach could potentially end the organ shortage crisis and transform the lives of thousands of people waiting for transplants.

Keywords: Biotechnology, Healthcare, Organ Transplantation, Genetic Engineering, Porcine Organs, Human Compatible Organs, Organ Shortage, Life-saving, High Demand, Innovative.

Company overview

EGenesis company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2015
Headquarters
Cambridge, United States
Employees
153
Open positions
9
Dealroom signal
86.3
client focusb2bsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorDNAsectorGenetics and genomicssectorSynthetic BiologysectorCrisprsectorSpinoutsectorGenome EngineeringsectorRumoured $1BsectorBiotech and PharmasectorDT and LS

Valuation & funding

EGenesis funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Sep 2024 $191M $764M Farallon Capital Management · Alta Partners · ARCH Venture Partners · Parkwood
SERIES COther financing Mar 2021 $125M $500M Wellington Partners · Farallon Capital Management · Polaris Partners · Khosla Ventures
SERIES BOther financing Nov 2019 $100M $400M Khosla Ventures · Alta Partners · Biomatics Capital Partners · Fresenius Medical Care
SERIES AOther financing Mar 2017 $38M $152M Khosla Ventures · Berggruen Holdings · Heritage Provider Network · ARCH Venture Partners
CONVERTIBLEOther financing Aug 2016 $2M Khosla Ventures
SPINOUTOther financing Jan 2015 Harvard University
Showing 6 recorded eventsUnlock the complete deal history →

Growth signals

EGenesis website traffic

Latest recorded traffic for EGenesis is 9.4K monthly website visits, up 118.6% over the last three months. EGenesis's team grew 12.5% over the past year.

Latest monthly visits9.4K 3-month web change+118.6% 1-year team growth+12.5%
Monthly website visits104 observations · Oct 2017–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

EGenesis compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Caribou BiosciencesBiotechnology company focused on genome engineering and developing technology-based solutions for cells Berkeley, United States Operational 128 $190M $82M
Intellia TherapeuticsA leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases Cambridge, United States Operational
SynthegoProvider of synthetic RNA solutions for CRISPR genome engineering Menlo Park, United States Acquired
Editas MedicineUnlocking the promise of genome editing to deliver life-changing medicines Cambridge, United States Operational
Pioneer BiolabsB2B biomanufacturing company leveraging its proprietary genomic screening platform to engineer and optimize microbial cells for protein production Provo, United States Operational
Affini-T TherapeuticsBiotechnology company developing T-cell therapies for patients suffering from cancer Boston, United States Operational
Octant BioDeveloping synthetic technology and applying next-generation DNA sequencing, gene synthesis, and gene editing to discover safer, more effective, cheaper drugs Emeryville, United States Operational
Locus BiosciencesA biotechnology company that develops CRISPR-engineered precision antibacterial products Morrisville, United States Operational
Showing 8 of the closest matchesCompare every metric →

Talent graph

EGenesis's talent

Book a demo to see the people
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

28 investors on EGenesis's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 9 investors entered at this stage
Khosla Ventures
ARCH Venture Partners
Biomatics Capital Partners
Berggruen Holdings
Heritage Provider Network
Alta Partners
Alexandria Venture Investments
Fresenius Medical Care
Wellington Partners
Series B+ 18 investors entered at this stage
Farallon Capital Management
Polaris Partners
Osage University Partners
Irving Investors
Samsara BioCapital
Monashee Investment Management
Fresenius Medical Care Ventures
Altium Capital
Invus
LifeSci Venture Partners
SymBiosis
Leaps by Bayer
Catalio Capital Management
Lux Capital
Parkwood
DaVita
NATCO Pharma
Eisai Innovation
Other known 1 additional known investor
Harvard University

Global footprint

Where EGenesis has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States97.2%
🇬🇧 United Kingdom0.9%
🇩🇪 Germany0.9%
3 countries shown

In the news

Latest news about EGenesis

Recent press, funding announcements, and product moves mentioning EGenesis — open to read from the original sources.

See all news

Market sentiment

What the market is saying about EGenesis

An AI-synthesized read of the highest-engagement posts about EGenesis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EGenesis’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.